Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long

Organs-on-chips are at the forefront of preclinical innovation, promising to usher in a new era of patient-centric drug development.

Clinical trials have long depended on a rigid, site-based model that excludes many potential participants, but decentralized clinical trials (DCTs) are changing that by bringing research directly to patients through telemedicine, wearables, and remote monitoring solutions. Accelerated by the COVID-19 pandemic, DCTs offer greater accessibility and diversity, though compliance, data integrity, and equity challenges remain. We explore why a hybrid model may define clinical resea